• Publications
  • Influence
Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.
Oxaliplatin is a clinical anticancer drug with a pharmacological profile distinct from that of cisplatin. Our studies compared site- and region-specificity of lesions induced by oxaliplatin andExpand
  • 212
  • 8
  • PDF
The N Terminus of Bradykinin When Bound to the Human Bradykinin B2 Receptor Is Adjacent to Extracellular Cys20 and Cys277 in the Receptor*
Chemical cross-linking combined with site-directed mutagenesis was used to evaluate the role of extracellular cysteines and their positions relative to the binding site for the agonist bradykininExpand
  • 29
  • 5
B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by
In this study we investigated receptor-specific cellular signals elicited by kinin agonists in cultured rabbit superior mesenteric artery smooth muscle cells. Kinins promoted an increase in inositolExpand
  • 67
  • 4
Oxaliplatin-induced damage of cellular DNA.
Damage to cellular DNA is believed to determine the antiproliferative properties of platinum (Pt) drugs. This study characterized DNA damage by oxaliplatin, a diaminocyclohexane Pt drug with clinicalExpand
  • 253
  • 2
  • PDF
The Agonist Binding Site on the Bovine Bradykinin B2 Receptor Is Adjacent to a Sulfhydryl and Is Differentiated from the Antagonist Binding Site by Chemical Cross-linking (*)
Chemical cross-linking was used to analyze the binding sites for the agonist bradykinin (BK) and the antagonists NPC17731 and HOE140 on the bovine B2 bradykinin receptor. [3H]BK and [3H]NPC17731Expand
  • 25
  • 2
Matrix attachment region (MAR) properties and abnormal expansion of AT island minisatellites in FRA16B fragile sites in leukemic CEM cells.
AT-rich minisatellites (AT islands) are sites of genomic instability in cancer cells and targets for extremely lethal AT-specific drugs, such as bizelesin. Here we investigated the AT islands in theExpand
  • 21
  • 2
  • PDF
Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).
This investigation compared the effects of hydroxymethylacylfulvene (HMAF), a novel antitumor drug with alkylating properties, in eight human tumor (prostate, colon, and leukemia) cell lines, andExpand
  • 51
  • 1
Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).
Hydroxymethylacylfulvene (HMAF, MGI 114) is a novel antitumor drug and a potent pro-apoptotic agent that has the potential to alkylate cellular nucleophiles. The objective of these studies was toExpand
  • 46
  • 1
Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific.
Tallimustine (FCE 24517) is an AT-specific alkylating antitumor derivative of distamycin. This study examined levels of tallimustine lesions in intracellular DNA, their sequence- andExpand
  • 13
  • 1
Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells.
Several B2 bradykinin (BK) receptor-specific antagonists including HOE140, NPC17731, and NPC567 exhibited negative intrinsic activity, which was observed as a decrease in basal phosphoinositideExpand
  • 79